4-氨基甲基肉桂酸 | 104566-34-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 4-氨基甲基肉桂酸
• 英文名称: 4-aminomethyl-cinnamic acid
• 英文别名: 4-Aminomethyl-zimtsaeure；β-(4-Aminomethyl-phenyl)-acrylsaeure；4-(2-Carboxy-trans-ethenyl)benzylamine；(E)-3-[4-(aminomethyl)phenyl]prop-2-enoic acid
• CAS: 104566-34-9
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: PFLNNPDZFNVJFF-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氨基甲基肉桂酸 在 palladium charcoal ethereal hydrochloric acid 作用下， 以 甲醇 为溶剂， 生成 4-氨甲基-苯丙酸甲酯(HCL)
  参考文献：
  名称：

  Cyclic imino derivatives and pharmaceutical compositions containing them

  摘要：

  这项发明涉及具有有价值的药理特性，特别是对细胞聚集具有抑制作用的环亚胺化合物，包含这些化合物的药物组合物以及制备它们的方法。

  公开号：

  US05541343A1
• 作为产物：
  描述：

  4-[(2-chloro-acetylamino)-methyl]-cinnamic acid 在 盐酸 作用下， 生成 4-氨基甲基肉桂酸
  参考文献：
  名称：

  Einhorn; Goettler, Chemische Berichte, 1909, vol. 42, p. 4847

  摘要：

  DOI：

文献信息

• [EN] ALKYNYL ARYL CARBOXAMIDES<br/>[FR] ALKYNYLARYL-CARBOXAMIDES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2005012280A1

  公开（公告）日：2005-02-10

  The present invention is related to alkynyl aryl carboxamides of Formula (I’) and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance. insulin resistance, hyperlipidemia, hypertriglyceridemia- hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkynyl aryl carboxamides of Formula (I’) to modulate, notably to inhibit the activity of PTPs. (I’) A is a C2-C15 alkynyl, C2-C6-alkynyl aryl, C2-C6-alkynyl heteroaryl. Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group; n is either 0 or 1. Cy' is an aryl., which may optionally be fused by a 3-8 membered cycloalkyl. R1and R2 are independently from each other is selected from the group consisting of hydrogen or (CI-C6)alkyl. R4and R5 are each independently from each other selected from the group consisting of H, hydroxy. C1 -C6 alkyl, carboxy, C1-C6 alkoxy, C1 -C3 alkyl carboxy, C2-C3 alkenyl carboxy, C2-C3 alkynyl carboxy, amino or R4 and R5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R4 or R5 is not a hydrogen or C1-C6 alkyl.

  本发明涉及式(I')的炔基芳基羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的炎症疾病、肥胖和/或代谢紊乱的使用，包括I型和/或II型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高脂血症、高甘油三酯血症-高胆固醇血症、多囊卵巢综合征(PCOS)。特别是，本发明涉及使用式(I')的炔基芳基羧酰胺来调节，尤其是抑制PTPs的活性。(I') A是C2-C15炔基，C2-C6-炔基芳基，C2-C6-炔基杂芳基。Cy是芳基、杂芳基、环烷基或杂环族；n是0或1。Cy'是一个芳基，它可以选择性地通过一个3-8成员的环烷基融合。R1和R2独立地互选自由氢或(C1-C6)烷基组成的组。R4和R5各自独立地互选自H、羟基。C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成一个不饱和或饱和的杂环，其中至少R4或R5不是氢或C1-C6烷基。
• 3(2H)pyridazinone, process for its preparation and anti-allergic agent
  申请人：Nissan Chemical Industries Ltd.

  公开号：US05098900A1

  公开（公告）日：1992-03-24

  A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is C.sub.2 -C.sub.5 alkyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.3 alkyl, chlorine or bromine; R.sub.3 is hydrogen or C.sub.1 -C.sub.4 alkyl; and each of Y.sub.1, Y.sub.2 and Y.sub.3 which may be the same or different, is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --(CH.sub.2).sub.l A [wherein A is substituted amino of the formula --N(R.sub.4) (R.sub.5) (wherein each of R.sub.4 and R.sub.5 which may be the same or different, is C.sub.1 -C.sub.4 alkyl, or R.sub.4 and R.sub.5 together form C.sub.4 -C.sub.6 alkylene), morpholino, 4-R.sub.6 -piperazin-1-yl (wherein R.sub.6 is C.sub.1 -C.sub.3 alkyl) or --OR.sub.7 (wherein R.sub.7 is hydrogen or C.sub.1 -C.sub.3 alkyl), and l is an integer of 0 to 3], --OR.sub.8 [wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.5 alkenyl, benzyl or --(CH.sub.2).sub.q --R.sub.9 [wherein R.sub.9 is CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CONHR.sub.3 (wherein R.sub.3 is as defined above) or --CH.sub.2 OR.sub.7 (wherein R.sub.7 is as defined above), and q is an integer of 1 to 5]], --CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CON(R.sub.10) (R.sub.11) [wherein each of R.sub.10 and R.sub.11 which may be the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.5 alkenyl, or R.sub.10 and R.sub.11 together form C.sub.4 -C.sub.6 alkylene, --(CH.sub.2).sub.2 O(CH.sub.2).sub.2 -- or --(CH.sub.2).sub.2 N(R.sub.6)(CH.sub.2).sub.2 -- (wherein R.sub.6 is as defined above)], --CONH(CH.sub.2).sub.m A (wherein A is as defined above, and m is an integer of 2 to 4), --CH.dbd.CHCOR.sub.12 (wherein R.sub.12 is hydroxy, C.sub.1 -C.sub.4 alkoxy or --N(R.sub.13) (CH.sub.2).sub.n CO.sub.2 R.sub.3 (wherein R.sub.13 is hydrogen, C.sub.1 -C.sub.6 alkyl or cycloalkyl, R.sub.3 is as defined above, and n is an integer of 1 to 4)), --SR.sub.14 (wherein R.sub.14 is C.sub.1 -C.sub.4 alkyl), --CN or ##STR2## wherein R.sub.3 is as defined above), or two of Y.sub.1, Y.sub.2 and Y.sub.3 together form ##STR3## (wherein p is an integer of 1 or 2), and a pharmaceutically acceptable salt thereof.

  该化合物为公式：##STR1## 其中R.sub.1为C.sub.2-C.sub.5烷基；R.sub.2为氢、C.sub.1-C.sub.3烷基、氯或溴；R.sub.3为氢或C.sub.1-C.sub.4烷基；每个Y.sub.1、Y.sub.2和Y.sub.3（可以相同或不同）为氢、C.sub.1-C.sub.8烷基、C.sub.2-C.sub.8烯基、卤素、--（CH.sub.2）.sub.l A [其中A为公式--N（R.sub.4）（R.sub.5）的取代氨基（其中R.sub.4和R.sub.5可以相同或不同，为C.sub.1-C.sub.4烷基，或R.sub.4和R.sub.5一起形成C.sub.4-C.sub.6亚烷基），morpholino、4-R.sub.6-piperazin-1-yl（其中R.sub.6为C.sub.1-C.sub.3烷基）或--OR.sub.7（其中R.sub.7为氢或C.sub.1-C.sub.3烷基），l为0至3的整数]，--OR.sub.8 [其中R.sub.8为氢、C.sub.1-C.sub.8烷基、C.sub.3-C.sub.5烯基、苄基或--（CH.sub.2）.sub.q--R.sub.9 [其中R.sub.9为CO.sub.2R.sub.3（其中R.sub.3如上所述），--CONHR.sub.3（其中R.sub.3如上所述）或--CH.sub.2OR.sub.7（其中R.sub.7如上所述），q为1至5的整数]，--CO.sub.2R.sub.3（其中R.sub.3如上所述），--CON（R.sub.10）（R.sub.11）[其中每个R.sub.10和R.sub.11可以相同或不同，为氢、C.sub.1-C.sub.4烷基或C.sub.3-C.sub.5烯基，或R.sub.10和R.sub.11一起形成C.sub.4-C.sub.6亚烷基，--（CH.sub.2）.sub.2O（CH.sub.2）.sub.2--或--（CH.sub.2）.sub.2N（R.sub.6）（CH.sub.2）.sub.2--（其中R.sub.6如上所述）]，--CONH（CH.sub.2）.sub.mA（其中A如上所述，m为2至4的整数），--CH.dbd.CHCOR.sub.12（其中R.sub.12为羟基、C.sub.1-C.sub.4烷氧基或--N（R.sub.13）（CH.sub.2）.sub.nCO.sub.2R.sub.3（其中R.sub.13为氢、C.sub.1-C.sub.6烷基或环烷基，R.sub.3如上所述，n为1至4的整数）），--SR.sub.14（其中R.sub.14为C.sub.1-C.sub.4烷基），--CN或##STR2##（其中R.sub.3如上所述），或Y.sub.1、Y.sub.2和Y.sub.3中的两个一起形成##STR3##（其中p为1或2的整数），以及其药学上可接受的盐。
• Alkynyl aryl carboxamides
  申请人：Swinnen Dominique

  公开号：US20070105913A1

  公开（公告）日：2007-05-10

  The present invention is related to alkynyl aryl carboxamides of Formula (I′) and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia-hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkynyl aryl carboxamides of Formula (I′) to modulate, notably to inhibit the activity of PTPs. (I′) A is a C 2 -C 15 alkynyl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl. Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group; n is either 0 or 1. Cy′ is an aryl., which may optionally be fused by a 3-8 membered cycloalkyl. R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen or (C 1 -C 6 )alkyl. R 4 and R 5 are each independently from each other selected from the group consisting of H, hydroxy. C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, C 2 -C 3 alkynyl carboxy, amino or R 4 and R 5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R 4 or R 5 is not a hydrogen or C 1 -C 6 alkyl.

  本发明涉及公式（I'）的炔基芳基羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的炎症性疾病、肥胖和/或代谢紊乱，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酸甘油酯血症-高胆固醇血症、多囊卵巢综合征（PCOS）。特别地，本发明涉及使用公式（I'）的炔基芳基羧酰胺来调节，特别是抑制PTP的活性。 （I'）中，A是C2-C15炔基、C2-C6炔基芳基、C2-C6炔基杂芳基。Cy是芳基、杂芳基、环烷基或杂环基；n为0或1。Cy'是芳基，可以选择与3-8个成员的环烷基融合。R1和R2分别独立地选自羟基或（C1-C6）烷基的群。R4和R5各自独立地选自H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成不饱和或饱和的杂环，其中R4或R5中至少有一个不是氢或C1-C6烷基。
• FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR
  申请人：Japan Tobacco, Inc.

  公开号：EP1719773B1

  公开（公告）日：2009-04-15
• Cyclische Iminoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
  申请人：Dr. Karl Thomae GmbH

  公开号：EP0483667B1

  公开（公告）日：1998-02-04